Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 160 Lymphoid 82 Genitourinary 29 Myeloid 21 Breast 7 Sarcoma 6 Classical hematology 6 Gynecologic 4 Tumor-Agnostic 2 Plasma cell 2 Head & Neck 1 Endocrine 1

Conditions

Thyroid Cancer, Papillary 1

Interventions

Cisplatin 619 pembrolizumab 323 Radiotherapy 319 Cetuximab 274 Docetaxel 220 Radiotherapy, Intensity-Modulated 210 Carboplatin 197 Fluorouracil 196 Paclitaxel 159 Nivolumab 138 Gemcitabine 124 Magnetic Resonance Spectroscopy 94 Radiation 85 Drug Therapy 77 Capecitabine 76 toripalimab 74 Surgical Procedures, Operative 62 durvalumab 60 Biopsy 52 Cyclophosphamide 48 Chemoradiotherapy 47 camrelizumab 46 Specimen Handling 46 Erlotinib Hydrochloride 46 Radiosurgery 45 130-nm albumin-bound paclitaxel 43 tislelizumab 42 Standard of Care 42 Platinum 41 Bevacizumab 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Mitoxantrone × Head & Neck × Clear all

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡